Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spermosens ABXSAT:SPERM Earnings Yield (Joel Greenblatt) % is -30.30% as of Jun. 2026. The stock has 1 warning sign investors should review. Among 213 Medical Diagnostics & Research companies, Spermosens AB ranks worse than 86.38% on this metric.
Spermosens AB's Enterprise Value for the quarter that ended in Jun. 2026 was kr31.12 Mil.
Spermosens AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was kr-9.44 Mil. Spermosens AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -30.30%.
The historical rank and industry rank for Spermosens AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XSAT:SPERM'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -36.2 Med: 0 Max: 0
Current: -35.34
XSAT:SPERM's Earnings Yield (Joel Greenblatt) % is ranked worse than 86.38% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 0
vs XSAT:SPERM: -35.34
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Spermosens AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Spermosens AB (XSAT:SPERM) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Spermosens AB Earnings Yield (Joel Greenblatt) % Related Terms
Spermosens AB Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Spermosens AB's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spermosens AB Earnings Yield (Joel Greenblatt) % Chart
For the Diagnostics & Research subindustry, Spermosens AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spermosens AB Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Spermosens AB's Earnings Yield (Joel Greenblatt) % falls into.
Spermosens AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Spermosens ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Spermosens AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-9.44 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -30.30% mean?
Spermosens AB (XSAT:SPERM) has a Earnings Yield (Joel Greenblatt) % of -30.30% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Spermosens AB and its competitors. According to the industry distribution chart, Spermosens AB ranks #184 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 86.4%.
Is Spermosens AB's Earnings Yield (Joel Greenblatt) % too high?
Spermosens AB's current Earnings Yield (Joel Greenblatt) % is -30.30%. Based on the distribution chart, Spermosens AB ranks #184 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Spermosens AB's Earnings Yield (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spermosens AB ranks #184 out of 213 companies for Earnings Yield (Joel Greenblatt) %. This places Spermosens AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Spermosens AB and its competitors. Spermosens AB's current Earnings Yield (Joel Greenblatt) % is -30.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spermosens AB stock overvalued right now?
Spermosens AB (XSAT:SPERM) has a current Earnings Yield (Joel Greenblatt) % of -30.30%. The current Earnings Yield (Joel Greenblatt) % is -30.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Spermosens AB (XSAT:SPERM), the current Earnings Yield (Joel Greenblatt) % is -30.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:SPERM has been successfully added to your 
